HIT Consultant

FEBRUARY 13, 2024

Precedent exists for accelerating approval timelines during health emergencies such as the AIDs/HIV epidemic, where Compound S, a re-make of AZT, or azidothymidine, originally developed to fight cancer, became controversially fast-tracked after the discovery that it could block HIV activity.

Patient Advocacy 98

Patient Advocacy Public Health Health Outcomes 98

HIT Consultant

MAY 17, 2023

Erin Jospe, Chief Healthcare Advisor, World Wide Technology There has been a newfound effort to highlight and address the disparity in health outcomes for patients who belong to one or more marginalized communities.

Ransomware 96

Ransomware Health Outcomes Patient Advocacy 96

Hall Render

FEBRUARY 24, 2023

Dunleavy adds $9M to budget to address food stamp, Medicaid backlog New study provides snapshot of increase in maternal deaths in Alaska Mental Health Trust Grants $1.6M medical workers 4 takeaways from Braselton hospital expansion presentation HAWAII Hawaii Gov.

Nursing Homes 40

Nursing Homes COVID-19 Nurses Hospitals 40

Health Law Advisor

JULY 21, 2023

3] The FDA created the voluntary Breakthrough Devices Program to expedite the development, assessment, and review for premarket approval, 510(k) clearance, and de novo marketing authorization for devices designated as “breakthrough devices” to improve timely access for patients and providers. [4]

FDA 52

FDA Medicare Medicare Patient Advocacy 52